| Company/Division name | Spark Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 575 |
| City reshored to: | Philadelphia |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Manufacturing/engineering joint innovation (R&D), Skilled workforce availability/training |
